



![]() |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma |
|
Authors | ![]() | |
Published in | British journal of cancer. 2014, vol. 110, no. 11, p. 2655-2661 | |
Abstract | Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma. | |
Keywords | Adult — Aged — Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity — Brain Neoplasms/mortality/therapy — Chemoradiotherapy — Dacarbazine/administration & dosage/analogs & derivatives — Disease-Free Survival — Female — Glioblastoma/mortality/therapy — Humans — Male — Maximum Tolerated Dose — Middle Aged — Niacinamide/administration & dosage/analogs & derivatives — Phenylurea Compounds/administration & dosage — Treatment Outcome | |
Identifiers | DOI: 10.1038/bjc.2014.209 PMID: 24786603 | |
Full text | ||
Structures | ||
Research groups | Groupe Schaller Karl Lothard (neurochirurgie) (851) Immunothérapie des cancers (42) Traits génétiques complexes (901) | |
Citation (ISO format) | HOTTINGER, A F et al. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. In: British journal of cancer, 2014, vol. 110, n° 11, p. 2655-2661. doi: 10.1038/bjc.2014.209 https://archive-ouverte.unige.ch/unige:90881 |